• European Commission approved German public support for Sanofi's new Frankfurt insulin plant in September 2026.
• Support comes from Germany's federal government, the state of Hesse and the city of Frankfurt.
• Construction began today, with full insulin active ingredient production planned for 2032, subject to licensing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190630OMX_____CNEWS_EN_GNW1001278638_en) on October 19, 2026, and is solely responsible for the information contained therein.